HCW Biologics Inc.

0.43
-0.06 (-11.89%)
At close: Feb 10, 2025, 3:59 PM
0.41
-4.63%
After-hours Feb 10, 2025, 07:59 PM EST
undefined%
Bid 0.41
Market Cap 16.26M
Revenue (ttm) -
Net Income (ttm) -
EPS (ttm) -1.01
PE Ratio (ttm) -0.43
Forward PE n/a
Analyst Buy
Ask 0.45
Volume 795,948
Avg. Volume (20D) 15,939,563
Open 0.44
Previous Close 0.49
Day's Range 0.40 - 0.48
52-Week Range 0.21 - 2.52
Beta undefined

About HCWB

HCW Biologics Inc., a preclinical stage biopharmaceutical company, focuses on discovering and developing novel immunotherapies for chronic, low-grade inflammation, and age-related diseases. The company's lead products include HCW9218, which is an injectable immunotherapeutic for patients with pancreatic, ovarian, breast, prostate, and colorectal cancers, as well as pulmonary fibrosis; and HCW9302 for auto-immune diseases, such as alopecia areata ...

Industry Biotechnology
Sector Healthcare
IPO Date Jul 20, 2021
Employees 45
Stock Exchange NASDAQ
Ticker Symbol HCWB

Analyst Forecast

According to 1 analyst ratings, the average rating for HCWB stock is "Buy." The 12-month stock price forecast is $undefined, which is a decrease of NaN% from the latest price.

Buy 100.00%
Hold 0.00%
Sell 0.00%
Stock Forecasts
1 week ago
+128.58%
HCW Biologics shares are trading higher after the ... Unlock content with Pro Subscription
2 months ago
+320.91%
HCW Biologics shares are trading higher after the company entered into an exclusive licensing deal with WY Biotech for immunotherapy development.